Efficacy and safety of second-line treatment in Thai patients with primary warm-type autoimmune hemolytic anemia

Chattree Hantaweepant; Prat Pairattanakorn; Khemajira Karaketklang; Weerapat Owattanapanich; Yingyong Chinthammitr

doi:10.1080/16078454.2019.1671060

Efficacy and safety of second-line treatment in Thai patients with primary warm-type autoimmune hemolytic anemia

Chattree Hantaweepant, Prat Pairattanakorn, Khemajira Karaketklang, Weerapat Owattanapanich, Yingyong Chinthammitr

In: Hematology · 2019 · vol. 24(1) , pp. 720–726 · doi:10.1080/16078454.2019.1671060 · PMID:31581907 · W2978322355

article OA: gold CC0

📄 Open PDF View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by claude@2026-06, 2026-06-11 ⓘ

This study examined the efficacy and safety of second-line immunosuppressive drug treatment for primary warm-type autoimmune hemolytic anemia in Thai patients, noting a common relapse rate.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Immunosuppressive drugs are the most common second-line treatment for primary warm-type AIHA in Thailand; however, relapse was common. Additional therapies are needed to reduce the relapse rate and prolong remission.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (39)

Current treatment strategies in autoimmune hemolytic disorders via openalex
Danazol as first-line therapy for aplastic anemia via openalex
Hemolytic anemia due to warm autoantibodies via openalex
Immune Hemolysis: Diagnosis and Treatment Recommendations via openalex
Treatment of autoimmune hemolytic anemias via openalex
doi:10.1182/blood-2016-11-693689 via openalex
doi:10.1016/j.lpm.2014.02.009 via openalex
W21071181 via openalex
W128812423 via openalex
doi:10.1177/1076029615622002 via openalex
doi:10.1016/j.amjsurg.2012.05.030 via openalex
doi:10.1053/jinf.2001.0904 via openalex
doi:10.1080/1744666x.2018.1521722 via openalex
doi:10.1586/ehm.11.60 via openalex
doi:10.1016/s0248-8663(02)00688-4 via openalex
doi:10.1161/circulationaha.110.015008 via openalex
doi:10.1159/000206903 via openalex
doi:10.1016/j.jviscsurg.2017.06.011 via openalex
doi:10.1136/bmj.282.6281.2023 via openalex
doi:10.1002/(sici)1096-8652(199906)61:2<98::aid-ajh4>3.0.co;2-g via openalex
doi:10.1007/s00508-008-0945-1 via openalex
doi:10.1159/000438731 via openalex
doi:10.1080/10245330500345587 via openalex
doi:10.1016/j.autrev.2015.07.001 via openalex
doi:10.1080/10245332.2016.1138621 via openalex
doi:10.1182/blood.v89.4.1121 via openalex
doi:10.1182/blood-2014-06-583021 via openalex
doi:10.1016/0002-9343(67)90168-4 via openalex
doi:10.3324/haematol.12682 via openalex
doi:10.1016/j.autrev.2014.11.014 via openalex
doi:10.1001/jama.1985.03350360072021 via openalex
doi:10.1111/bjh.12541 via openalex
doi:10.1002/ajh.23767 via openalex
doi:10.1046/j.1198-743x.2001.00355.x via openalex
doi:10.1111/j.1600-0609.1977.tb02719.x via openalex
doi:10.1182/blood-2011-05-347708 via openalex
doi:10.1182/blood-2010-03-259325 via openalex
doi:10.1001/archsurg.1985.01390290099017 via openalex
doi:10.1002/ajh.10062 via openalex

SciLite annotations

chemicals 9

corticosteroid corticosteroid steroid steroid azathioprine cyclophosphamide chlorambucil danazol rituximab

Source provenance

openalex: last seen: 2026-05-10T10:25:40.298144+00:00
scilite: last seen: 2026-05-18T04:26:01.642840+00:00

License: CC0 · commercial use OK

[1] Current treatment strategies in autoimmune hemolytic disorders via openalex

[2] Danazol as first-line therapy for aplastic anemia via openalex

[3] Hemolytic anemia due to warm autoantibodies via openalex

[4] Immune Hemolysis: Diagnosis and Treatment Recommendations via openalex

[5] Treatment of autoimmune hemolytic anemias via openalex

[6] doi:10.1182/blood-2016-11-693689 via openalex

[7] doi:10.1016/j.lpm.2014.02.009 via openalex

[8] W21071181 via openalex

[9] W128812423 via openalex

[10] doi:10.1177/1076029615622002 via openalex

[11] doi:10.1016/j.amjsurg.2012.05.030 via openalex

[12] doi:10.1053/jinf.2001.0904 via openalex

[13] doi:10.1080/1744666x.2018.1521722 via openalex

[14] doi:10.1586/ehm.11.60 via openalex

[15] doi:10.1016/s0248-8663(02)00688-4 via openalex

[16] doi:10.1161/circulationaha.110.015008 via openalex

[17] doi:10.1159/000206903 via openalex

[18] doi:10.1016/j.jviscsurg.2017.06.011 via openalex

[19] doi:10.1136/bmj.282.6281.2023 via openalex

[20] doi:10.1002/(sici)1096-8652(199906)61:2<98::aid-ajh4>3.0.co;2-g via openalex

[21] doi:10.1007/s00508-008-0945-1 via openalex

[22] doi:10.1159/000438731 via openalex

[23] doi:10.1080/10245330500345587 via openalex

[24] doi:10.1016/j.autrev.2015.07.001 via openalex

[25] doi:10.1080/10245332.2016.1138621 via openalex

[26] doi:10.1182/blood.v89.4.1121 via openalex

[27] doi:10.1182/blood-2014-06-583021 via openalex

[28] doi:10.1016/0002-9343(67)90168-4 via openalex

[29] doi:10.3324/haematol.12682 via openalex

[30] doi:10.1016/j.autrev.2014.11.014 via openalex

[31] doi:10.1001/jama.1985.03350360072021 via openalex

[32] doi:10.1111/bjh.12541 via openalex

[33] doi:10.1002/ajh.23767 via openalex

[34] doi:10.1046/j.1198-743x.2001.00355.x via openalex

[35] doi:10.1111/j.1600-0609.1977.tb02719.x via openalex

[36] doi:10.1182/blood-2011-05-347708 via openalex

[37] doi:10.1182/blood-2010-03-259325 via openalex

[38] doi:10.1001/archsurg.1985.01390290099017 via openalex

[39] doi:10.1002/ajh.10062 via openalex